Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
DBV Technologies reported its third quarter 2021 financial results on October 26, 2021, showing a net loss of $24.0 million, a decrease from $31.0 million in Q3 2020. Cash and cash equivalents fell to $98.2 million from $196.4 million at the end of 2020. Operating expenses decreased by 24% to $25.7 million, primarily due to cost containment measures and workforce reduction. Regulatory updates indicate the FDA is reviewing data before the STAMP trial can proceed, while EMA discussions are ongoing regarding Viaskin Peanut's Marketing Authorization.
DBVT announced its monthly update on voting rights and total shares as of September 30, 2021. The company disclosed a total of 55,011,687 shares outstanding, with 54,936,287 shares having voting rights. This report follows Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The data is crucial for shareholders and investors to monitor ownership and voting power within the company.
DBVT announced the voting rights and total shares as of August 31, 2021. The company holds 55,011,687 total shares, with a total gross of 55,011,687 voting rights and a total net of 54,963,687 voting rights, accounting for shares without voting rights. This data is provided in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The shares are listed on the NYSE Euronext Paris market, under the ISIN Code: FR 0010417345.
DBV Technologies (DBVT) has announced participation in several virtual investor conferences in September 2021. The events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, followed by Citi's 16th Annual BioPharma Virtual Conference on September 8. Additionally, a pre-recorded fireside chat will be made available on September 13 at 7:00 AM ET during the H.C. Wainwright 23rd Annual Global Investment Conference. Investors can access the webcast and replay on the company’s website.
DBVT has released its monthly update regarding the total number of shares and voting rights as of July 31, 2021. The total number of shares is reported at 55,011,687, while the total number of voting rights stands at 55,011,687 gross and 54,942,087 net. This update is in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The company's ISIN code is FR 0010417345.
DBV Technologies (Euronext: DBV – Nasdaq: DBVT) has released its Half-Year report detailing its liquidity contract with ODDO BHF as of June 30, 2021. The liquidity account held 77,875 shares and €480,481.63 in assets, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. During the second half of 2020, a total of 1,105 purchases and 1,146 sales were executed, with 461,457 shares bought for €4.3 million and 495,884 shares sold for €4.5 million.
DBV Technologies reported its second quarter 2021 financial results on August 2, 2021, highlighting progress in the development of its Viaskin Peanut patch. The company submitted a protocol for a critical study to the FDA and completed an adhesion trial, selecting two superior patch designs. Cash and cash equivalents stood at $125.5 million, down from $196.4 million at year-end 2020, expected to support operations until mid-2022. DBV's net loss narrowed to $30.7 million for Q2 2021, down from $48.2 million the previous year, with significant reductions in operating expenses attributed to budget discipline measures.
DBV Technologies, a clinical-stage biopharmaceutical company, will report its first half 2021 financial results and business updates on August 2, 2021. A conference call and live audio webcast will take place at 5:00 p.m. ET. Viaskin™, the company's investigational platform for immunotherapy, aims to transform the care of food allergic patients, with ongoing trials for Viaskin Peanut. The presentation will be available on their website, along with a replay post-event.
As of June 30, 2021, the total number of shares for the company was 55,011,687. This included 54,933,812 voting rights after accounting for shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is crucial for investors monitoring voting power and company governance. The data is available on the NYSE Euronext Paris market under the ISIN Code: FR 0010417345.
As of May 31, 2021, the company reported a total of 55,011,687 shares outstanding. The total gross voting rights are also at 55,011,687, while the net voting rights stand at 54,943,413. This announcement complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
